Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018042017) VACCINES FOR NEISSERIA GONORRHOEAE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/042017 International Application No.: PCT/EP2017/072011
Publication Date: 08.03.2018 International Filing Date: 01.09.2017
IPC:
A61K 39/095 (2006.01) ,C07K 16/12 (2006.01) ,C07K 14/22 (2006.01) ,A61K 39/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
02
Bacterial antigens
095
Neisseria
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
12
against material from bacteria
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
195
from bacteria
22
from Neisseriaceae (F), e.g. Acinetobacter
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
Applicants:
GLAXOSMITHKLINE BIOLOGICALS SA [BE/BE]; rue de l'Institut 89 B-1330 Rixensart, BE
Inventors:
PIZZA, Mariagrazia; IT
GIULIANI, Marzia, Monica; IT
MONACI, Elisabetta; IT
Agent:
KLACZYNSKA, Sarah Elizabeth; GB
Priority Data:
62/383,13402.09.2016US
Title (EN) VACCINES FOR NEISSERIA GONORRHOEAE
(FR) VACCINS CONTRE NEISSERIA GONORRHOEAE
Abstract:
(EN) A method for immunizing a subject in need thereof against Neisseria gonorrhoeae by administering an immunogenic composition comprising one or more of the following: (i) a NHBA antigen; (ii) a fHbp antigen; (iii) a NadA antigen; (iv) a GNA1030 antigen; (v) a GNA2091 antigen; (vi) one or more of (i) to (v) above in combination with conjugated capsular saccharide from meningococcal serogroups A, C, W135 and Y.
(FR) L'invention concerne une méthode d'immunisation d'un sujet ayant besoin d'un tel traitement contre Neisseria gonorrhoeae par administration d'une composition immunogène comprenant un ou plusieurs des éléments suivants : (i) un antigène NHBA ; (ii) un antigène fHbp ; (iii) un antigène NadA ; (iv) un antigène GNA1030 ; (v) un antigène GNA2091 ; (vi) un ou plusieurs des éléments (i) à (v) susmentionnés en association avec un saccharide capsulaire conjugué issu des sérogroupes méningococciques A, C, W135 et Y.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)